FY2022 EPS Estimates for Gilead Sciences, Inc. Raised by Jefferies Financial Group (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) – Analysts at Jefferies Financial Group raised their FY2022 earnings estimates for Gilead Sciences in a note issued to investors on Tuesday, August 2nd. Jefferies Financial Group analyst M. Yee now forecasts that the biopharmaceutical company will earn $6.67 per share for the year, up from their prior forecast of $6.59. The consensus estimate for Gilead Sciences’ current full-year earnings is $6.58 per share. Jefferies Financial Group also issued estimates for Gilead Sciences’ Q4 2023 earnings at $1.55 EPS, FY2023 earnings at $6.34 EPS and FY2024 earnings at $6.82 EPS.

Several other equities analysts also recently weighed in on GILD. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a report on Tuesday, July 12th. They issued a “neutral” rating and a $70.00 price target on the stock. Piper Sandler cut their price target on shares of Gilead Sciences from $73.00 to $69.00 and set a “neutral” rating on the stock in a report on Monday, May 16th. Royal Bank of Canada raised their price objective on shares of Gilead Sciences from $76.00 to $77.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 12th. BMO Capital Markets assumed coverage on shares of Gilead Sciences in a research note on Tuesday, June 7th. They set a “hold” rating and a $63.00 price objective on the stock. Finally, TheStreet cut shares of Gilead Sciences from a “b-” rating to a “c+” rating in a research note on Friday, July 1st. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $72.07.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $61.09 on Friday. The firm has a market capitalization of $76.63 billion, a P/E ratio of 18.63, a PEG ratio of 0.63 and a beta of 0.34. The company has a quick ratio of 1.30, a current ratio of 1.49 and a debt-to-equity ratio of 1.31. The company has a 50 day moving average price of $61.55 and a 200 day moving average price of $61.93. Gilead Sciences has a 52 week low of $57.17 and a 52 week high of $74.12.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Arrowstreet Capital Limited Partnership grew its holdings in shares of Gilead Sciences by 324.8% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock valued at $1,070,232,000 after acquiring an additional 13,764,169 shares in the last quarter. Norges Bank bought a new position in shares of Gilead Sciences in the 4th quarter valued at about $950,911,000. Capital World Investors grew its holdings in shares of Gilead Sciences by 16.0% in the 1st quarter. Capital World Investors now owns 49,501,852 shares of the biopharmaceutical company’s stock valued at $2,942,905,000 after acquiring an additional 6,820,228 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Gilead Sciences by 70.6% in the 1st quarter. Renaissance Technologies LLC now owns 15,492,116 shares of the biopharmaceutical company’s stock valued at $921,006,000 after acquiring an additional 6,410,047 shares in the last quarter. Finally, First Trust Advisors LP grew its holdings in shares of Gilead Sciences by 103.4% in the 1st quarter. First Trust Advisors LP now owns 6,126,685 shares of the biopharmaceutical company’s stock valued at $364,232,000 after acquiring an additional 3,114,535 shares in the last quarter. 80.16% of the stock is currently owned by institutional investors.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 29th. Investors of record on Thursday, September 15th will be given a dividend of $0.73 per share. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $2.92 dividend on an annualized basis and a yield of 4.78%. Gilead Sciences’s dividend payout ratio (DPR) is presently 89.02%.

Gilead Sciences Company Profile

(Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Further Reading

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.